Bioequivalence and Bioavailability Forum 00:58 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Kim Christoper

2018-06-29 10:42

Posting: # 18994
Views: 331

 Bio batch for Phase 1 [Regulatives / Guidelines]

Dear, Mr. Helmut.
Good to see you.
I have one question about bio batch.
I already searched about my doubt in this website, but i can't get enough answer, so I write this sentences.

We plan to proceed the Phase 1 IND in US in soon.
So, we will use the CMO for Biobatch.

Pharmaceutical is, Capsule, and Antibiotics.

At this point,
  1. I wonder if the production scale at the clinical stage can produce only the required quantity for clinical trials.

  2. (After that), I wonder if production is possible regardless of the scale produced in the clinical trial in the PV batch.

  3. I wonder if Phase 1 must produce more than 100,000 units.

  4. If we can produce less than 100,000 units, I wonder if we should produce more than 100,000 units in Phase 2 and 3.

  5. Also, I wonder what kind of data is needed for the consistency of biobatch to be used in Phase 1 and Phase 2 and 3.

Thank you very much for your help.
Back to the forum Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,698 posts in 3,983 threads, 1,234 registered users;
online 14 (0 registered, 14 guests [including 13 identified bots]).

When puzzled, it never hurts to read the primary documents –
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

BEBAC Ing. Helmut Schütz